aTyr Pharma (LIFE) Cut to Underweight at JPMorgan Chase & Co.
aTyr Pharma (NASDAQ:LIFE) was downgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Wednesday, The Fly reports.
Other equities analysts also recently issued research reports about the company. Zacks Investment Research upgraded aTyr Pharma from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Saturday, November 18th. ValuEngine downgraded aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $4.81.
Shares of aTyr Pharma (NASDAQ:LIFE) opened at $3.50 on Wednesday. The company has a quick ratio of 9.49, a current ratio of 9.49 and a debt-to-equity ratio of 0.17. aTyr Pharma has a 52-week low of $2.30 and a 52-week high of $6.50. The company has a market capitalization of $101.18, a P/E ratio of -1.72 and a beta of 3.60.
Several institutional investors have recently bought and sold shares of LIFE. Artal Group S.A. lifted its position in shares of aTyr Pharma by 100.0% during the 4th quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after buying an additional 250,000 shares during the period. Renaissance Technologies LLC lifted its position in shares of aTyr Pharma by 143.2% during the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after buying an additional 164,500 shares during the period. Victory Capital Management Inc. bought a new position in shares of aTyr Pharma during the 3rd quarter worth approximately $455,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after buying an additional 25,676 shares during the period. Institutional investors and hedge funds own 58.00% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.